Publicaciones en las que colabora con Esteban Daudén Tello (35)

2024

  1. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting

    International Journal of Dermatology, Vol. 63, Núm. 4, pp. 503-511

2023

  1. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  2. Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice

    Journal of the European Academy of Dermatology and Venereology

  3. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)

    Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345

  4. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

    International Journal of Dermatology

  5. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice

    Journal of the European Academy of Dermatology and Venereology

2022

  1. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting

    Dermatologic Therapy, Vol. 35, Núm. 8

  2. Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience

    Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406

  3. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients

    Dermatologic Therapy, Vol. 35, Núm. 12

  4. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry

    Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117

  5. Ustekinumab to guselkumab transitions: A series of 54 patients emulating the navigate trial in real life

    Dermatologic Therapy, Vol. 35, Núm. 10

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

  2. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

    Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517

  3. Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain

    Dermatology and Therapy, Vol. 11, Núm. 6, pp. 2207-2215

2020

  1. A retrospective, observational multicenter study of 141 patients treated with ustekinumab 90 mg

    Dermatologic Therapy, Vol. 33, Núm. 4

  2. Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry

    Actas Dermo-Sifiliograficas, Vol. 111, Núm. 9, pp. 752-760

  3. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry

    Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150

  4. The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study

    Dermatologic Therapy, Vol. 33, Núm. 6

2019

  1. Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis

    Journal of the European Academy of Dermatology and Venereology, Vol. 33, Núm. 7, pp. 1214-1223

  2. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364